All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Brought to you by

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Types Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

MPN Types

2021-01-08T14:32:14.000Z

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis?

By Amalia Zachariadis, Paola Frisone, Becky Gribbell

Featured

Srdan Verstovsek

Jan 8, 2021

Bookmark this article

Video series

ASH 2020 highlights for myelofibrosis

1

6:05

What do the preliminary results of the MANIFEST trial say about CPI-0610...

Alessandro M. Vannucchi

2

4:03

SIMPLIFY-1+2 trial: What is the long-term benefit of momelotinib treatment...

Ruben A. Mesa

3:56

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with...

Srdan Verstovsek

4

4:10

Why does adding navitoclax to ruxolitinib induce responses in patients...

Naveen Pemmaraju

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center, Houston, US. We asked, Does the bromodomain and extraterminal domain (BET) inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis (MF)?

The use of the JAK inhibitor ruxolitinib is standard practice for most patients with MF. However, it does not control all the systemic symptoms in all patients. In this video, Verstovsek discusses the results of the phase II MANIFEST study investigating the BET inhibitor CPI-0610 in combination with ruxolitinib in patients with MF.